Co-Authors
This is a "connection" page, showing publications co-authored by Lanying Du and Wanbo Tai.
Connection Strength
4.412
-
A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2. Cell Res. 2020 10; 30(10):932-935.
Score: 0.896
-
Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2. Antiviral Res. 2020 07; 179:104820.
Score: 0.882
-
Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020 06; 17(6):613-620.
Score: 0.873
-
Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants. J Virol. 2017 Jan 01; 91(1).
Score: 0.696
-
Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines. Nat Commun. 2016 11 22; 7:13473.
Score: 0.173
-
A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection. Virology. 2016 12; 499:375-382.
Score: 0.172
-
Vaccines for the prevention against the threat of MERS-CoV. Expert Rev Vaccines. 2016 09; 15(9):1123-34.
Score: 0.166
-
The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates. Elife. 2021 08 02; 10.
Score: 0.060
-
Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2 protein-protein interaction. Biophys J. 2021 03 16; 120(6):1011-1019.
Score: 0.058
-
The Potency of an Anti-MERS Coronavirus Subunit Vaccine Depends on a Unique Combinatorial Adjuvant Formulation. Vaccines (Basel). 2020 May 27; 8(2).
Score: 0.055
-
Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry. J Virol. 2020 02 14; 94(5).
Score: 0.054
-
Enhanced Ability of Oligomeric Nanobodies Targeting MERS Coronavirus Receptor-Binding Domain. Viruses. 2019 02 19; 11(2).
Score: 0.051
-
A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV. J Virol. 2018 09 15; 92(18).
Score: 0.049
-
Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen. Vaccine. 2018 03 27; 36(14):1853-1862.
Score: 0.047
-
Cryo-Electron Microscopy Structure of Porcine Deltacoronavirus Spike Protein in the Prefusion State J Virol. 2018 02 15; 92(4).
Score: 0.047
-
Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses. Sci China Life Sci. 2017 12; 60(12):1399-1402.
Score: 0.046
-
Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection. Hum Vaccin Immunother. 2017 07 03; 13(7):1615-1624.
Score: 0.044
-
Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection. Antiviral Res. 2016 08; 132:141-8.
Score: 0.042